Logo image of CRSP

CRISPR THERAPEUTICS AG (CRSP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRSP - CH0334081137 - Common Stock

53.47 USD
+0.17 (+0.32%)
Last: 11/28/2025, 8:21:39 PM
53.7 USD
+0.23 (+0.43%)
After Hours: 11/28/2025, 8:21:39 PM
Fundamental Rating

3

Taking everything into account, CRSP scores 3 out of 10 in our fundamental rating. CRSP was compared to 534 industry peers in the Biotechnology industry. While CRSP has a great health rating, there are worries on its profitability. CRSP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRSP has reported negative net income.
CRSP had a negative operating cash flow in the past year.
CRSP had negative earnings in 4 of the past 5 years.
CRSP had negative operating cash flow in 4 of the past 5 years.
CRSP Yearly Net Income VS EBIT VS OCF VS FCFCRSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

1.2 Ratios

CRSP has a Return On Assets of -21.75%. This is in the better half of the industry: CRSP outperforms 74.34% of its industry peers.
Looking at the Return On Equity, with a value of -25.49%, CRSP is in the better half of the industry, outperforming 79.96% of the companies in the same industry.
Industry RankSector Rank
ROA -21.75%
ROE -25.49%
ROIC N/A
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
CRSP Yearly ROA, ROE, ROICCRSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRSP Yearly Profit, Operating, Gross MarginsCRSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

8

2. Health

2.1 Basic Checks

CRSP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRSP has been increased compared to 1 year ago.
Compared to 5 years ago, CRSP has more shares outstanding
CRSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRSP Yearly Shares OutstandingCRSP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRSP Yearly Total Debt VS Total AssetsCRSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

CRSP has an Altman-Z score of 8.43. This indicates that CRSP is financially healthy and has little risk of bankruptcy at the moment.
CRSP has a Altman-Z score of 8.43. This is in the better half of the industry: CRSP outperforms 79.21% of its industry peers.
There is no outstanding debt for CRSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.43
ROIC/WACCN/A
WACC4.96%
CRSP Yearly LT Debt VS Equity VS FCFCRSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

CRSP has a Current Ratio of 16.22. This indicates that CRSP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CRSP (16.22) is better than 93.26% of its industry peers.
CRSP has a Quick Ratio of 16.22. This indicates that CRSP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CRSP (16.22) is better than 93.26% of its industry peers.
Industry RankSector Rank
Current Ratio 16.22
Quick Ratio 16.22
CRSP Yearly Current Assets VS Current LiabilitesCRSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

4

3. Growth

3.1 Past

CRSP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.30%.
The Revenue for CRSP has decreased by -81.10% in the past year. This is quite bad
Measured over the past years, CRSP shows a very negative growth in Revenue. The Revenue has been decreasing by -33.62% on average per year.
EPS 1Y (TTM)-58.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.84%
Revenue 1Y (TTM)-81.1%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%47.67%

3.2 Future

The Earnings Per Share is expected to grow by 15.52% on average over the next years. This is quite good.
The Revenue is expected to grow by 173.75% on average over the next years. This is a very strong growth
EPS Next Y-44.52%
EPS Next 2Y0.48%
EPS Next 3Y5.75%
EPS Next 5Y15.52%
Revenue Next Year94.07%
Revenue Next 2Y208.98%
Revenue Next 3Y175.37%
Revenue Next 5Y173.75%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRSP Yearly Revenue VS EstimatesCRSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
CRSP Yearly EPS VS EstimatesCRSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRSP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRSP Price Earnings VS Forward Price EarningsCRSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRSP Per share dataCRSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.48%
EPS Next 3Y5.75%

More info and screens

0

5. Dividend

5.1 Amount

CRSP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRISPR THERAPEUTICS AG

NASDAQ:CRSP (11/28/2025, 8:21:39 PM)

After market: 53.7 +0.23 (+0.43%)

53.47

+0.17 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)02-09 2026-02-09/amc
Inst Owners81%
Inst Owner Change-0.93%
Ins Owners1.64%
Ins Owner Change0.45%
Market Cap5.10B
Revenue(TTM)38.34M
Net Income(TTM)-488.30M
Analysts76.67
Price Target80.31 (50.2%)
Short Float %23.51%
Short Ratio7.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.79%
Min EPS beat(2)8.57%
Max EPS beat(2)11%
EPS beat(4)3
Avg EPS beat(4)14.7%
Min EPS beat(4)-23.86%
Max EPS beat(4)63.08%
EPS beat(8)6
Avg EPS beat(8)210.14%
EPS beat(12)10
Avg EPS beat(12)155.51%
EPS beat(16)11
Avg EPS beat(16)115.33%
Revenue beat(2)0
Avg Revenue beat(2)-88.12%
Min Revenue beat(2)-90.21%
Max Revenue beat(2)-86.02%
Revenue beat(4)1
Avg Revenue beat(4)20.13%
Min Revenue beat(4)-90.21%
Max Revenue beat(4)343.7%
Revenue beat(8)2
Avg Revenue beat(8)-18.1%
Revenue beat(12)4
Avg Revenue beat(12)325.02%
Revenue beat(16)5
Avg Revenue beat(16)256.51%
PT rev (1m)-2.46%
PT rev (3m)-0.92%
EPS NQ rev (1m)-6.04%
EPS NQ rev (3m)-2.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.16%
Revenue NQ rev (1m)0.53%
Revenue NQ rev (3m)-18.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-28.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 132.92
P/FCF N/A
P/OCF N/A
P/B 2.66
P/tB 2.66
EV/EBITDA N/A
EPS(TTM)-4.48
EYN/A
EPS(NY)-4.33
Fwd EYN/A
FCF(TTM)-3.44
FCFYN/A
OCF(TTM)-3.17
OCFYN/A
SpS0.4
BVpS20.1
TBVpS20.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.75%
ROE -25.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.4%
ROA(5y)-11.51%
ROE(3y)-20.59%
ROE(5y)-13.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 137.47%
Cap/Sales 66.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.22
Quick Ratio 16.22
Altman-Z 8.43
F-Score2
WACC4.96%
ROIC/WACCN/A
Cap/Depr(3y)74.64%
Cap/Depr(5y)175.56%
Cap/Sales(3y)1036.11%
Cap/Sales(5y)1149.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.84%
EPS Next Y-44.52%
EPS Next 2Y0.48%
EPS Next 3Y5.75%
EPS Next 5Y15.52%
Revenue 1Y (TTM)-81.1%
Revenue growth 3Y-65.58%
Revenue growth 5Y-33.62%
Sales Q2Q%47.67%
Revenue Next Year94.07%
Revenue Next 2Y208.98%
Revenue Next 3Y175.37%
Revenue Next 5Y173.75%
EBIT growth 1Y-43.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.2%
EBIT Next 3Y6.33%
EBIT Next 5Y20.04%
FCF growth 1Y-11.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.97%
OCF growth 3YN/A
OCF growth 5YN/A

CRISPR THERAPEUTICS AG / CRSP FAQ

What is the fundamental rating for CRSP stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRSP.


Can you provide the valuation status for CRISPR THERAPEUTICS AG?

ChartMill assigns a valuation rating of 0 / 10 to CRISPR THERAPEUTICS AG (CRSP). This can be considered as Overvalued.


What is the profitability of CRSP stock?

CRISPR THERAPEUTICS AG (CRSP) has a profitability rating of 1 / 10.


How financially healthy is CRISPR THERAPEUTICS AG?

The financial health rating of CRISPR THERAPEUTICS AG (CRSP) is 8 / 10.